Full Text View
Tabular View
No Study Results Posted
Related Studies
Orexigenic Therapy With Delta-9-Tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study
This study is currently recruiting participants.
Study NCT00316563   Information provided by Alberta Cancer Board
First Received: April 19, 2006   Last Updated: December 4, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Anorexia
Taste Disorders
Olfactory Disorders
Additional conditions recognized in this trial
Congenital Abnormalities
Disease
More general conditions related to this trial
Nervous System Diseases
Neurologic Manifestations
Pathologic Processes
Sensation Disorders
Signs and Symptoms
Signs and Symptoms, Digestive
Interventions listed in this trial
Marinol (Dronabinol)
Placebo
Additional drug interventions recognized in this trial
Tetrahydrocannabinol
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Central Nervous System Agents
Hallucinogens
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Alberta Cancer Board
University of Alberta


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services